In vitro and in vivo correlation of the effect of granulocyte-macrophage colony-stimulating factor gene transfer on the tumorigenicity and immunogenicity of B16 melanoma

Jie Wang, Sung Jan Wei, Wen K. Yang, Wen Chang Lin, Den Mei Yang, Jacqueline Whang-Peng, Chou Chik Ting

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Transduction of murine B16 melanoma cells with a GM-CSF gene, the B16-MG tumor line, showed reduced tumorigenicity. In vitro studies demonstrated no remarkable difference between the parent and transduced tumor lines in their ability to induce secondary response to generate the anti-tumor killer cells (immunogenicity), or in their susceptibility to the killing by anti-tumor killer cells (immunosensitivity). Both CD4+ and CD8+ cells were required for the generation of the effectors. Nevertheless the effectors were determined to be Thy 1.2+, CD8-, and NK1.1-. At least two antigenic specificities could be defined in the cytolytic reactions. One was a broadly cross-reactive antigen shared by a variety of tumor cells, and the other apparently a tumor-specific antigen which was only present in B16 tumors. Cold target inhibition experiment confirmed these specificities. In the in vivo tumor transplantation study, the B16-MG cell line was not only more immunogenic but also was more immunosensitive than the parent line. More than 50% of the mice which were immunized with B16-MG remained tumor free after challenge with the parent tumor B16, indicating that GM-CSF gene transfer makes an effective tumor vaccine. The in vivo protective effect was specific for B16 tumor, thus only the tumor-specific antigen could function as transplantation antigen. Both CD4+ and CD8+ cells were required for providing the in vivo protection. Both the B16 and B16-MG tumor bearing hosts could generate anti-tumor killer cells, hence the development of progressive growth of B16 tumor was not due to the lack of anti-tumor immune response. It appears that the overall effect of in vivo tumor immunity is determined by a complex network of interactions among different compartments of host immune cells and different immuno-regulatory molecules derived from the host and from the tumor.

Original languageEnglish
Pages (from-to)1267-1276
Number of pages10
JournalInternational Journal of Oncology
Volume9
Issue number6
Publication statusPublished - Dec 1 1996
Externally publishedYes

Fingerprint

Experimental Melanomas
Granulocyte-Macrophage Colony-Stimulating Factor
Genes
Neoplasms
In Vitro Techniques
Neoplasm Antigens
Cancer Vaccines
Histocompatibility Antigens
Growth and Development

Keywords

  • gene transfer
  • GM-CSF
  • tumor immunity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

In vitro and in vivo correlation of the effect of granulocyte-macrophage colony-stimulating factor gene transfer on the tumorigenicity and immunogenicity of B16 melanoma. / Wang, Jie; Wei, Sung Jan; Yang, Wen K.; Lin, Wen Chang; Yang, Den Mei; Whang-Peng, Jacqueline; Ting, Chou Chik.

In: International Journal of Oncology, Vol. 9, No. 6, 01.12.1996, p. 1267-1276.

Research output: Contribution to journalArticle

@article{ff0a7e26236640d4b567ca1b80a83411,
title = "In vitro and in vivo correlation of the effect of granulocyte-macrophage colony-stimulating factor gene transfer on the tumorigenicity and immunogenicity of B16 melanoma",
abstract = "Transduction of murine B16 melanoma cells with a GM-CSF gene, the B16-MG tumor line, showed reduced tumorigenicity. In vitro studies demonstrated no remarkable difference between the parent and transduced tumor lines in their ability to induce secondary response to generate the anti-tumor killer cells (immunogenicity), or in their susceptibility to the killing by anti-tumor killer cells (immunosensitivity). Both CD4+ and CD8+ cells were required for the generation of the effectors. Nevertheless the effectors were determined to be Thy 1.2+, CD8-, and NK1.1-. At least two antigenic specificities could be defined in the cytolytic reactions. One was a broadly cross-reactive antigen shared by a variety of tumor cells, and the other apparently a tumor-specific antigen which was only present in B16 tumors. Cold target inhibition experiment confirmed these specificities. In the in vivo tumor transplantation study, the B16-MG cell line was not only more immunogenic but also was more immunosensitive than the parent line. More than 50{\%} of the mice which were immunized with B16-MG remained tumor free after challenge with the parent tumor B16, indicating that GM-CSF gene transfer makes an effective tumor vaccine. The in vivo protective effect was specific for B16 tumor, thus only the tumor-specific antigen could function as transplantation antigen. Both CD4+ and CD8+ cells were required for providing the in vivo protection. Both the B16 and B16-MG tumor bearing hosts could generate anti-tumor killer cells, hence the development of progressive growth of B16 tumor was not due to the lack of anti-tumor immune response. It appears that the overall effect of in vivo tumor immunity is determined by a complex network of interactions among different compartments of host immune cells and different immuno-regulatory molecules derived from the host and from the tumor.",
keywords = "gene transfer, GM-CSF, tumor immunity",
author = "Jie Wang and Wei, {Sung Jan} and Yang, {Wen K.} and Lin, {Wen Chang} and Yang, {Den Mei} and Jacqueline Whang-Peng and Ting, {Chou Chik}",
year = "1996",
month = "12",
day = "1",
language = "English",
volume = "9",
pages = "1267--1276",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - In vitro and in vivo correlation of the effect of granulocyte-macrophage colony-stimulating factor gene transfer on the tumorigenicity and immunogenicity of B16 melanoma

AU - Wang, Jie

AU - Wei, Sung Jan

AU - Yang, Wen K.

AU - Lin, Wen Chang

AU - Yang, Den Mei

AU - Whang-Peng, Jacqueline

AU - Ting, Chou Chik

PY - 1996/12/1

Y1 - 1996/12/1

N2 - Transduction of murine B16 melanoma cells with a GM-CSF gene, the B16-MG tumor line, showed reduced tumorigenicity. In vitro studies demonstrated no remarkable difference between the parent and transduced tumor lines in their ability to induce secondary response to generate the anti-tumor killer cells (immunogenicity), or in their susceptibility to the killing by anti-tumor killer cells (immunosensitivity). Both CD4+ and CD8+ cells were required for the generation of the effectors. Nevertheless the effectors were determined to be Thy 1.2+, CD8-, and NK1.1-. At least two antigenic specificities could be defined in the cytolytic reactions. One was a broadly cross-reactive antigen shared by a variety of tumor cells, and the other apparently a tumor-specific antigen which was only present in B16 tumors. Cold target inhibition experiment confirmed these specificities. In the in vivo tumor transplantation study, the B16-MG cell line was not only more immunogenic but also was more immunosensitive than the parent line. More than 50% of the mice which were immunized with B16-MG remained tumor free after challenge with the parent tumor B16, indicating that GM-CSF gene transfer makes an effective tumor vaccine. The in vivo protective effect was specific for B16 tumor, thus only the tumor-specific antigen could function as transplantation antigen. Both CD4+ and CD8+ cells were required for providing the in vivo protection. Both the B16 and B16-MG tumor bearing hosts could generate anti-tumor killer cells, hence the development of progressive growth of B16 tumor was not due to the lack of anti-tumor immune response. It appears that the overall effect of in vivo tumor immunity is determined by a complex network of interactions among different compartments of host immune cells and different immuno-regulatory molecules derived from the host and from the tumor.

AB - Transduction of murine B16 melanoma cells with a GM-CSF gene, the B16-MG tumor line, showed reduced tumorigenicity. In vitro studies demonstrated no remarkable difference between the parent and transduced tumor lines in their ability to induce secondary response to generate the anti-tumor killer cells (immunogenicity), or in their susceptibility to the killing by anti-tumor killer cells (immunosensitivity). Both CD4+ and CD8+ cells were required for the generation of the effectors. Nevertheless the effectors were determined to be Thy 1.2+, CD8-, and NK1.1-. At least two antigenic specificities could be defined in the cytolytic reactions. One was a broadly cross-reactive antigen shared by a variety of tumor cells, and the other apparently a tumor-specific antigen which was only present in B16 tumors. Cold target inhibition experiment confirmed these specificities. In the in vivo tumor transplantation study, the B16-MG cell line was not only more immunogenic but also was more immunosensitive than the parent line. More than 50% of the mice which were immunized with B16-MG remained tumor free after challenge with the parent tumor B16, indicating that GM-CSF gene transfer makes an effective tumor vaccine. The in vivo protective effect was specific for B16 tumor, thus only the tumor-specific antigen could function as transplantation antigen. Both CD4+ and CD8+ cells were required for providing the in vivo protection. Both the B16 and B16-MG tumor bearing hosts could generate anti-tumor killer cells, hence the development of progressive growth of B16 tumor was not due to the lack of anti-tumor immune response. It appears that the overall effect of in vivo tumor immunity is determined by a complex network of interactions among different compartments of host immune cells and different immuno-regulatory molecules derived from the host and from the tumor.

KW - gene transfer

KW - GM-CSF

KW - tumor immunity

UR - http://www.scopus.com/inward/record.url?scp=0029833161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029833161&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 1267

EP - 1276

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -